IL4 and asthma: The anti-interleukin-4 receptor α monoclonal antibody (Dupilumab) that blocks both interleukin-4 and interleukin-13 signaling significantly decreased the rates of severe asthma exacerbation, as well as improved lung function and better asthma control [70].